Uta Kemmerich-Keil Appointed Non-Executive Director to British American Tobacco Board

British American Tobacco (BAT) announced the appointment of Uta Kemmerich-Keil as a Non-Executive Director to its Main Board, effective 17 February 2025. She will serve on the Audit and Nominations Committees. Kemmerich-Keil brings extensive transformational and M&A experience from the consumer goods and pharmaceutical sectors, having previously served as CEO of Personal Healthcare International at Procter & Gamble and held leadership roles at Merck Group, including CEO of its Consumer Health Division and Head of Corporate M&A, Treasury and Finance. She also worked as a Senior Financial Auditor at Hoechst AG. Her current board positions include Non-Executive Director and Audit Chair of Beiersdorf AG, Non-Executive Director of Klosterfrau Healthcare Group and Schott AG, Director of Farco Pharma GmbH, and advisory board member of Röchling SE & Co KG. She previously served as a Non-Executive Director of Affimed N.V., Biotest AG, and Gothaer Krankenversicherung and Allgemeine Versicherung.